Literature DB >> 29467457

Adenylosuccinate lyase enhances aggressiveness of endometrial cancer by increasing killer cell lectin-like receptor C3 expression by fumarate.

Haengki Park1, Kenji Ohshima1, Satoshi Nojima1, Shinichiro Tahara1, Masako Kurashige1, Yumiko Hori1, Daisuke Okuzaki2, Naoki Wada1, Jun-Ichiro Ikeda1, Eiichi Morii3.   

Abstract

Adenylosuccinate lyase (ADSL) is an enzyme that plays important roles in de novo purine synthesis. Although ADSL was reported to be upregulated in various malignancies, such as colorectal, breast, and prostate cancer, as well as gliomas, the mechanism by which elevated ADSL expression contributes to cancer has not been elucidated. We previously performed a shotgun proteomics analysis to characterize specific proteins associated with the properties of the aldehyde dehydrogenase (ALDH)-high cell population, which was reported to be involved in tumorigenic potential, and showed that ADSL expression is upregulated in the ALDH-high population of endometrial cancer. Here, we showed that ADSL is involved in endometrial cancer aggressiveness by regulating expression of killer cell lectin-like receptor C3 (KLRC3), which is a receptor expressed on natural killer cells. Immunohistochemical analysis indicated that ADSL expression increased as endometrioid carcinoma specimens became more poorly differentiated and higher degree of primary tumor progression. Knockdown of ADSL in endometrial cancer cells decreased cell proliferation, migration, and invasive capability, and caused the cells to adopt a more rounded shape. DNA microarray analysis and quantitative real-time PCR showed that KLRC3 expression was decreased in ADSL knockdown cells. Knockdown of KLRC3 in endometrial cancer cells resulted in the same phenotype as knockdown of ADSL. Moreover, fumarate, which could be produced by ADSL and was recently shown to be an oncometabolite, recovered KLRC3 expression in ADSL knockdown cells, suggesting that fumarate produced by ADSL could regulate KLRC3 expression. Our findings indicate that ADSL enhances cell proliferation, migration, and invasive capability through regulation of KLRC3 expression by fumarate.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29467457     DOI: 10.1038/s41374-017-0017-0

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  31 in total

1.  The kinetics of adenylosuccinate lyase.

Authors:  W A Bridger; L H Cohen
Journal:  J Biol Chem       Date:  1968-02-10       Impact factor: 5.157

2.  Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications.

Authors:  Nur Rahadiani; Jun-ichiro Ikeda; Suhana Mamat; Shinya Matsuzaki; Yutaka Ueda; Reina Umehara; Tian Tian; Yi Wang; Takayuki Enomoto; Tadashi Kimura; Katsuyuki Aozasa; Eiichi Morii
Journal:  Cancer Sci       Date:  2011-02-09       Impact factor: 6.716

3.  Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells.

Authors:  John P Chute; Garrett G Muramoto; John Whitesides; Michael Colvin; Rachid Safi; Nelson J Chao; Donald P McDonnell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-20       Impact factor: 11.205

4.  Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.

Authors:  Feng Jiang; Qi Qiu; Abha Khanna; Nevins W Todd; Janaki Deepak; Lingxiao Xing; Huijun Wang; Zhenqiu Liu; Yun Su; Sanford A Stass; Ruth L Katz
Journal:  Mol Cancer Res       Date:  2009-03-10       Impact factor: 5.852

5.  Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Authors:  William Matsui; Qiuju Wang; James P Barber; Sarah Brennan; B Douglas Smith; Ivan Borrello; Ian McNiece; Lan Lin; Richard F Ambinder; Craig Peacock; D Neil Watkins; Carol Ann Huff; Richard J Jones
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

6.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

7.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Authors:  Christophe Ginestier; Min Hee Hur; Emmanuelle Charafe-Jauffret; Florence Monville; Julie Dutcher; Marty Brown; Jocelyne Jacquemier; Patrice Viens; Celina G Kleer; Suling Liu; Anne Schott; Dan Hayes; Daniel Birnbaum; Max S Wicha; Gabriela Dontu
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

8.  Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.

Authors:  Daniel J Pearce; David Taussig; Catherine Simpson; Kirsty Allen; Ama Z Rohatiner; T Andrew Lister; Dominique Bonnet
Journal:  Stem Cells       Date:  2005 Jun-Jul       Impact factor: 6.277

9.  S100A4 accelerates the proliferation and invasion of endometrioid carcinoma and is associated with the "MELF" pattern.

Authors:  Shinichiro Tahara; Satoshi Nojima; Kenji Ohshima; Yumiko Hori; Masako Kurashige; Naoki Wada; Jun-Ichiro Ikeda; Eiichi Morii
Journal:  Cancer Sci       Date:  2016-08-12       Impact factor: 6.716

10.  ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome.

Authors:  Ting Li; Yun Su; Yuping Mei; Qixin Leng; Bingjie Leng; Zhenqiu Liu; Sanford A Stass; Feng Jiang
Journal:  Lab Invest       Date:  2009-12-14       Impact factor: 5.662

View more
  10 in total

1.  Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function.

Authors:  Tingting Jiang; Francisco J Sánchez-Rivera; Yadira M Soto-Feliciano; Qiyuan Yang; Chun-Qing Song; Arjun Bhuatkar; Cole M Haynes; Michael T Hemann; Wen Xue
Journal:  Hepatology       Date:  2021-07-12       Impact factor: 17.298

2.  Serum deprivation-response protein regulates aldehyde dehydrogenase 1 through integrin-linked kinase signaling in endometrioid carcinoma cells.

Authors:  Shinichiro Tahara; Satoshi Nojima; Kenji Ohshima; Yumiko Hori; Masako Kurashige; Naoki Wada; Yuichi Motoyama; Daisuke Okuzaki; Jun-Ichiro Ikeda; Eiichi Morii
Journal:  Cancer Sci       Date:  2019-04-11       Impact factor: 6.716

3.  Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer.

Authors:  Giada Zurlo; Xijuan Liu; Mamoru Takada; Cheng Fan; Jeremy M Simon; Travis S Ptacek; Javier Rodriguez; Alex von Kriegsheim; Juan Liu; Jason W Locasale; Adam Robinson; Jing Zhang; Jessica M Holler; Baek Kim; Marie Zikánová; Jörgen Bierau; Ling Xie; Xian Chen; Mingjie Li; Charles M Perou; Qing Zhang
Journal:  Nat Commun       Date:  2019-11-15       Impact factor: 14.919

Review 4.  Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis.

Authors:  Kenji Ohshima; Eiichi Morii
Journal:  Metabolites       Date:  2021-01-02

5.  Tumor Metabolome: Therapeutic Opportunities Targeting Cancer Metabolic Reprogramming.

Authors:  Javier Márquez; José M Matés
Journal:  Cancers (Basel)       Date:  2021-01-16       Impact factor: 6.639

6.  Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis.

Authors:  Stephanie Taha-Mehlitz; Gaia Bianco; Mairene Coto-Llerena; Venkatesh Kancherla; Glenn R Bantug; John Gallon; Caner Ercan; Federica Panebianco; Serenella Eppenberger-Castori; Marco von Strauss; Sebastian Staubli; Martin Bolli; Ralph Peterli; Matthias S Matter; Luigi M Terracciano; Markus von Flüe; Charlotte K Y Ng; Savas D Soysal; Otto Kollmar; Salvatore Piscuoglio
Journal:  Theranostics       Date:  2021-02-15       Impact factor: 11.556

Review 7.  The Intersection of Purine and Mitochondrial Metabolism in Cancer.

Authors:  Humberto De Vitto; Danushka B Arachchige; Brian C Richardson; Jarrod B French
Journal:  Cells       Date:  2021-09-30       Impact factor: 6.600

8.  An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia.

Authors:  Michael Hamilton; Yutaka Shima; Jeevisha Bajaj; Kendall Chambers; Kyle Spinler; Eric L Van Nostrand; Brian A Yee; Steven M Blue; Michael Chen; David Rizzeri; Charles Chuah; Vivian G Oehler; H Elizabeth Broome; Roman Sasik; James Scott-Browne; Anjana Rao; Gene W Yeo; Tannishtha Reya
Journal:  Nat Cancer       Date:  2020-04-20

Review 9.  Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer.

Authors:  Martina Godel; Giacomo Ortone; Dario Pasquale Anobile; Martina Pasino; Giulio Randazzo; Chiara Riganti; Joanna Kopecka
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321

10.  A Metabolic Model of Intestinal Secretions: The Link between Human Microbiota and Colorectal Cancer Progression.

Authors:  Pejman Salahshouri; Modjtaba Emadi-Baygi; Mahdi Jalili; Faiz M Khan; Olaf Wolkenhauer; Ali Salehzadeh-Yazdi
Journal:  Metabolites       Date:  2021-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.